Navigation Links
ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services
Date:5/8/2009

NORFOLK, Va., May 8 /PRNewswire/ -- ValueOptions(R), Inc., the nation's largest independent behavioral health and wellness company, announces its support for the use of The Joint Commission's Hospital-Based Inpatient Psychiatric Services (HBIPS) performance measures. The basis for the recently completed pilot program was to establish a set of core performance measures to help patients receive the most appropriate and medically necessary treatment for psychiatric inpatient services and for services upon discharge. Following The Joint Commission's successful pilot testing, these performance measures are now available for widespread use in hospitals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090106/PH55551LOGO )

There are seven HBIPS performance measures in place for hospitals which are accredited by The Joint Commission:

  • Admission screening for violence risk, substance use, psychological trauma history and patient strengths
  • Hours of physical restraint use
  • Hours of seclusion use
  • Patients discharged on multiple antipsychotic medications
  • Patients discharged on multiple antipsychotic medications with appropriate justification
  • Post discharge continuing care plan created
  • Post discharge continuing care plan transmitted to next level of care provider upon discharge

"Coordination between Inpatient and Outpatient providers in these areas will help to ensure positive outcomes for members and their families," said Renee Abdou-Malta, vice president of National Network Services for ValueOptions(R). "We very much encourage our Joint Commission-accredited providers to work together in this manner."

"Thorough assessments which lead to individualized treatment plans as well as discharge coordination are areas that ValueOptions(R) advocates," said Hal Levine, D.O., chief medical officer for ValueOptions(R). "We routinely encourage hospitals to minimize their use of seclusion, restraint and polypharmacy. The Joint Commission's measures will help all parties involved to provide optimal services when treating members."

More information regarding The Joint Commission's HBIPS performance measures can be found on The Joint Commission's Web site.

About ValueOptions(R), Inc.

ValueOptions(R), Inc., the nation's largest independent behavioral health and wellness company, provides services to more than 23 million individuals through a variety of contracts with state and county agencies and, additionally, with health plans and employers. ValueOptions(R) is a national behavioral health and wellness company that specializes in management for all behavioral health issues and promotes health and wellness through innovative programs. ValueOptions(R) mission is to improve the health and wellness for the people it serves.

www.ValueOptions.com


'/>"/>
SOURCE ValueOptions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. First Human Study to Show Sun Chlorella A Supports Heart Health
2. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
3. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
4. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
5. APTA Supports Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
6. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
7. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
8. New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
11. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... Want to learn more about CRISPR-Cas ... that demonstrates how this advanced plant breeding technology is a more efficient way ... resources. It highlights the business’ principles, research and collaboration efforts in this area. ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a medical ... that it has received 510(k) clearance from the U.S. Food & Drug Administration ... Pro. , Both devices are stationary cycling systems that use MYOLYN’s patent-pending ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab ... to be the preferred physical therapy provider for Derby City CrossFit, effective immediately. ... City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... ... , ... Lake Park Dental is now accepting new patients with crooked teeth ... With the help of this highly-effective, yet convenient system, patients can straighten their teeth ... less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, ...
Breaking Medicine News(10 mins):